Glaucoma

MIGS with OMNI system linked with diminished diurnal IOP fluctuations, a risk factor for glaucoma progression

The 12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations.

Genetics give investigators a risk stratification in glaucoma

PRS can modify disease outcomes due to other genes, such as MYOC.

Study: Bimatoprost implant reduces IOP for 2 years or more

Felipe Medeiros, MD, presents results from a phase 3 clinical extension study of the bimatoprost implant that found patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fiends.